Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)
Note: The Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) ended enrollment on July 31, 2021. CDC continues to use its other flu vaccine effectiveness (VE) networks, including the Influenza and Other Viruses in the Acutely Ill (IVY) network, to collect information on adults hospitalized with flu.
The Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) was created to estimate how well the flu vaccine works at preventing severe flu illness, especially among older adults.
Flu Vaccine Effectiveness
Measuring vaccine effectiveness (VE) against flu hospitalizations in older adults is important because this group has the highest hospitalization rate compared to other age groups. Also, adults who are hospitalized may have more underlying conditions than adults receiving outpatient care (learn more: U.S. Flu VE Network).
CDC measures VE each year to evaluate the benefits of flu vaccines in different age groups and against different clinical outcomes, like hospitalization. These efforts inform U.S. vaccine recommendations and policy decisions aimed at providing the best protection from flu and its complications.
Other HAIVEN Studies
In addition to vaccine effectiveness, HAIVEN also describes severe flu outcomes in hospitalized adults, such as length of hospital stay, need for intensive care, and use of ventilation. Describing these outcomes helps us better understand the patients impacted by severe flu.
HAIVEN also studies respiratory infections in hospitalized older adults, including COVID-19, RSV, and human metapneumovirus.
Sites and Study Design
Participating sites are located in four states:
- For more information about how CDC’s VE studies are conducted and how to interpret results, see How Flu Vaccine Effectiveness and Efficacy are Measures: Questions and Answers for Health Professionals.
- See for a table that shows the overall adjusted VE and related references for each season starting in 2015-16.